Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle this.
1. Could you tell us a little about the FIL-DLCL04 study and its findings? (0:10)
2. What is the approximate percentage of patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation? (1:41)
3. What was the impact of TP53 mutations on the prognosis of these young patients with DLBCL? (3:03)
4. What treatment strategies are in clinical development for patients with DLBCL and a TP53 mutation? (4:01)
Speaker disclosures: Annalisa Chiappella has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018